Dishman Carbogen Amcis Ltd, a Contract Research and Manufacturing Services (CRAMS) provider saw its shares open 5 percent higher at Rs 90.05 compared to its previous close of Rs 86.05. During the early hours, it gained 10 to trade at Rs 100 levels.
The scrip gained after the company reported a 14 percent increase in revenue, which stood at Rs 639.79 Crore in Q3FY23 compared to Rs 562.08 Crore Year on Year. In the previous quarter, their revenue was Rs 613.96 Crore. Their revenue increased across all segments due to strong demand and a healthy order book.
The company reported a profit of Rs 46.96 Crore in the period compared to a loss of Rs 10.05 Crore in the September quarter. On a YoY basis, their profits increased by 33 percent from Rs 35.38 Crore.
Dishman Carbogen Amcis Ltd is engaged in Contract Research and Manufacturing Services (CRAMS) and manufacture and supply of marketable molecules such as specialty chemicals, vitamins & chemicals, and disinfectants. It has operations in India, Switzerland, the UK, France, China, and the Netherlands.
The company is focused on improving its capacity utilization at its manufacturing facilities by targeting small and mid-sized global biotech companies and diversifying across new geographies.
To further its goals, the company recently announced that its French subsidiary, CARBOGEN AMCIS opened a new state-of-the-art facility dedicated to sterile liquid drug product manufacturing in Saint- Beauzire, France. This was made with an investment of $50 million.
The small-cap company has a market capitalization of Rs 1,567 Crore. The stock is a part of not one but two Indian ace investors. Mukul Mahavir Agrawal holds 55,00,000 shares or a 3.51% stake with Rs 54.9 Crore holding value. While Rekha Rakesh Jhunjhunwala holds 25,50,000 shares or a 1.63% stake with a holding value of Rs 25.5 Crore.
Written by Anoushka Roy
Disclaimer
The content in this news article is not investment advice. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
